Clinical Drug Experience Knowledgebase

Neoplasms

Adenocarcinoma of Lung (Phase 2)

Adrenocortical Carcinoma (Phase 2)

Albumin-Bound Paclitaxel (Phase 2)

Allergy and Immunology (Phase 1)

Angiogenesis Modulating Agents (Phase 2)

Apoptosis (Phase 2)

Artificial Intelligence (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Biomarkers (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Bronchial Neoplasms (Phase 3)

Capecitabine (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Bronchogenic (Phase 3)

Carcinoma, Hepatocellular (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Carcinosarcoma (Phase 2)

Chemoembolization, Therapeutic (Phase 1/Phase 2)

Chemoradiotherapy (Phase 2)

Cholangiocarcinoma (Phase 2)

Chordoma (Phase 2)

Cisplatin (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Death (Phase 1)

Dendritic Cells (Phase 2)

Digestive System Neoplasms (Phase 2)

Disease-Free Survival (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Drugs, Investigational (Phase 3)

Drug Therapy (Phase 3)

Electroconvulsive Therapy (Phase 2)

Endometrial Neoplasms (Phase 2)

Endostatins (Phase 2)

Epstein-Barr Virus Infections (Phase 2/Phase 3)

Esophageal Diseases (Phase 2)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 2)

Gallbladder Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

General Surgery (Phase 3)

Genes, erbB-1 (Phase 2)

Genes, p53 (Phase 1)

Gestational Trophoblastic Disease (Phase 2)

Glioblastoma (Phase 2)

Granulocyte Colony-Stimulating Factor (Phase 2)

Head and Neck Neoplasms (Phase 2)

Herpesvirus 4, Human (Phase 2)

Hodgkin Disease (Phase 3)

Hyperbaric Oxygenation (Phase 1)

Hypopharyngeal Neoplasms (Phase 2)

Immune Checkpoint Inhibitors (Phase 3)

Immunotherapy (Phase 3)

Induction Chemotherapy (Phase 2)

Intestinal Neoplasms (Phase 2)

Killer Cells, Natural (Phase 2)

Lapatinib (Phase 2)

Leukemia, B-Cell (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Neoplasms (Phase 2)

Liver Transplantation (Phase 1/Phase 2)

Lung Diseases (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1/Phase 2)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, Follicular (Phase 1/Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1/Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 1/Phase 2)

Maintenance Chemotherapy (Phase 2)

Melanoma (Phase 3)

Microsatellite Instability (Phase 2)

Molecular Targeted Therapy (Phase 2)

Mouth Neoplasms (Phase 1)

Mutation (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Nasopharyngeal Carcinoma (Phase 3)

Nasopharyngeal Neoplasms (Phase 3)

Neoadjuvant Therapy (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms by Site (Phase 3)

Neoplasms, Connective and Soft Tissue (Phase 2)

Oncolytic Virotherapy (Phase 2)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Paranasal Sinus Neoplasms (Phase 2)

Pathology (Phase 2)

Pharmacokinetics (Phase 1/Phase 2)

Pleural Effusion, Malignant (Phase 1/Phase 2)

Progression-Free Survival (Phase 2)

Proto-Oncogene Proteins B-raf (Phase 1)

Radiotherapy (Phase 3)

ras GTPase-Activating Proteins (Phase 1)

ras Proteins (Phase 1)

Receptor, EphA2 (Phase 1)

Receptors, Vascular Endothelial Growth Factor (Phase 2)

Rectal Neoplasms (Phase 3)

Respiratory Tract Diseases (Phase 3)

Respiratory Tract Neoplasms (Phase 3)

Sarcoma (Phase 2)

Sezary Syndrome (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Stomach Neoplasms (Phase 3)

Survival (Phase 2)

Temozolomide (Phase 2)

Thoracic Neoplasms (Phase 3)

Thrombosis (Phase 2)

Thyroid Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 3)

Vinorelbine (Phase 2)